Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study
about
Long-Acting Injectable Paliperidone Palmitate: A Review of Efficacy and Safety.Dosing and Switching Strategies for Paliperidone Palmitate 3-Month Formulation in Patients with Schizophrenia Based on Population Pharmacokinetic Modeling and Simulation, and Clinical Trial Data.Physician and patient benefit-risk preferences from two randomized long-acting injectable antipsychotic trials.Cost-effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the Netherlands.Caregiver burden in schizophrenia following paliperidone palmitate long acting injectables treatment: pooled analysis of two double-blind randomized phase three studies.Cost-effectiveness of 3-month paliperidone treatment for chronic schizophrenia in Spain.The Use of Long-Acting Injectable Antipsychotics in Schizophrenia.Barriers to the Use of Long-Acting Injectable Antipsychotics in the Management of Schizophrenia.Paliperidone Palmitate Intramuscular 3-Monthly Formulation: A Review in Schizophrenia.Emerging pharmacological therapies in schizophrenia: what's new, what's different, what's next?Prospective dose selection and acceleration of paliperidone palmitate 3-month formulation development using a pharmacometric bridging strategySafety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study.Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study.Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia.Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review.A 6-Month Prospective Trial of a Personalized Behavioral Intervention + Long-Acting Injectable Antipsychotic in Individuals With Schizophrenia at Risk of Treatment Nonadherence and Homelessness.Baseline characteristics and treatment patterns of patients with schizophrenia initiated on once-every-three-months paliperidone palmitate in a real-world setting.Is paliperidone palmitate more effective than other long-acting injectable antipsychotics?Health care resource use analysis of paliperidone palmitate 3 month injection from two phase 3 clinical trials.Novel treatment options in depression and psychosis.Long-acting injectable antipsychotics update: lengthening the dosing interval and expanding the diagnostic indications.
P2860
Q33802918-7A47B004-2D11-4C75-B6D8-ADFA52DF1616Q36297118-9C518E88-7926-44E8-9732-7CA2CA49E4CEQ37376779-E7FC79BB-066D-486B-B75B-469837176E9CQ38649630-0FA5EC31-D532-4A54-BE0C-1B948CB8D720Q38656480-2E6ECF4A-4CFF-452B-9E18-850A67D2394DQ38692993-900EC72F-6221-4D9E-BA5E-204386298BAFQ38744570-51C7DCF7-6567-424F-8AEC-E0A0CF630E39Q38851847-14AB00E3-55B5-4426-917A-0514C26878AAQ38971631-29D91828-C3AB-49C2-A98A-3989F105E324Q39065466-F35E6C63-9062-46F2-9200-D641B556DE29Q39662882-D18B4652-224A-4962-8BE4-DE8E9B269D5DQ41283940-74B3E623-4E4E-456D-9234-866CA1AD7F30Q41483833-D05EE62C-F753-4D2A-9746-079AA5B7C9E2Q47154075-80EFA3FF-DE7A-44FC-81B7-DF8CD865822FQ47552120-31ACDBD9-57C3-4389-916A-2488ABF3F424Q47617662-363C61DC-45AB-4462-832B-FA8807B4C462Q47661583-D80EF62E-AE82-4A08-A039-114F24A83EB8Q47779069-50D15F1C-D073-41CF-BC1D-3BCFA4618825Q47962186-E885F8B4-B10B-495B-BC39-B108200A9185Q52646032-1AEC78DD-FB23-4359-A94C-89CAA59F60CEQ54217848-A0721737-B58F-4755-868B-D62CD9FC4ADE
P2860
Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 February 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Efficacy and Safety of Paliper ...... le-Blind, Noninferiority Study
@en
Efficacy and Safety of Paliper ...... e-Blind, Noninferiority Study.
@nl
type
label
Efficacy and Safety of Paliper ...... le-Blind, Noninferiority Study
@en
Efficacy and Safety of Paliper ...... e-Blind, Noninferiority Study.
@nl
prefLabel
Efficacy and Safety of Paliper ...... le-Blind, Noninferiority Study
@en
Efficacy and Safety of Paliper ...... e-Blind, Noninferiority Study.
@nl
P2093
P2860
P356
P1476
Efficacy and Safety of Paliper ...... le-Blind, Noninferiority Study
@en
P2093
Adam J Savitz
Adam Janik
Alain Schotte
David Hough
Isaac Nuamah
Paulien Ravenstijn
Srihari Gopal
Wolfgang W Fleischhacker
P2860
P356
10.1093/IJNP/PYW018
P577
2016-02-22T00:00:00Z